HK Stock MarketDetailed Quotes

02185 BIOHEART-B

Watchlist
  • 1.780
  • -0.080-4.30%
Market Closed Nov 15 16:08 CST
434.21MMarket Cap-3429P/E (TTM)

About BIOHEART-B Company

Shanghai Baixinan Biotechnology Co., Ltd. is a leading interventional cardiovascular device company in China. It is located in the Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. It focuses on two treatments, fully degradable stents (BRS) and renal nerve block (RDN), to address the unmet medical needs of Chinese patients with coronary and peripheral artery disease and hypertension. The company has a leased area of about 6,500 square meters, has a clean workshop of about 40 million square meters and testing laboratories for all projects of related products, has established a quality management system that meets ISO13485/YY0287 standards, gathers professionals in machinery, materials, precision processing, clinical medicine, etc., and has a team of experienced talents in product design, quality control, clinical verification, and market development.

Company Profile

Symbol02185
Company NameBIOHEART-B
ISINCNE100004JH3
Listing DateDec 23, 2021
Issue Price21.25
Shares Offered23.94M share(s)
FoundedJul 18, 2014
Registered AddressChina
Chairmanli wang
Secretaryzhaoyingwangyunqing guo
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeRoom 302, 3rd Floor, Building 4, No. 590 Ruiqing Road, East Zhangjiang Hi-Tech Industrial Zone, Pudong District, Shanghai, China
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees54
MarketHong Kong motherboard
Phone(021)68798511
Fax(021)68798512,(021)50722068
Emailinquiry@bio-heart.com
Websitehttp://www.bio-heart.com
Business Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the development and production of interventional cardiovascular devices. The company's main products include fully degradable stents (BRS) and renal nerve block (RDN). The company's products are mainly used to meet medical needs for treatment of coronary diseases, peripheral arterial diseases and high blood pressure.

Company Executives

  • Name
  • Position
  • Salary
  • li wang
  • Chairman, Executive Director, General Manager, Nomination Committee Members
  • 30.47M
  • yunqing wang
  • Executive Director, Chief Financial Officer, Joint Company Secretary, Board Secretary, Authorized Representative
  • 5.21M
  • peili wang
  • Executive Director, Financial Manager
  • 2.37M
  • yiqing chen
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members
  • --
  • xubo lu
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 400.00K
  • yifei jiang
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Audit Committee Members
  • --
  • tao cai
  • Technical Director (Fully Degradable Stent), auditors
  • 3.98M
  • lei zhu
  • Director of Quality Compliance, Auditors
  • 1.16M
  • junyi wang
  • Employee Representative Supervisor
  • 196.00K
  • Bradley Stewart Hubbard
  • Chief Medical Officer
  • --
  • zhaoying guo
  • Joint Company Secretary, Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data